相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study
G. Mustacchi et al.
ANNALS OF ONCOLOGY (2009)
Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902
Johanna G. H. van Nes et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
A. Barnadas et al.
BRITISH JOURNAL OF CANCER (2009)
Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial
Masafumi Kurosumi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)
Brigitte Mlineritsch et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)
Hiroyuki Takei et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version)
Masafumi Kurosumi et al.
BREAST CANCER (2008)
Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete Pathologic response after Neoadjuvant chemotherapy
Neal S. Goldstein et al.
CANCER (2007)
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy
Sadako Akashi-Tanaka et al.
BREAST (2007)
Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
R. Torrisi et al.
BRITISH JOURNAL OF CANCER (2007)
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
Vladimir F. Semiglazov et al.
CANCER (2007)
Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review
D. Hind et al.
BRITISH JOURNAL OF CANCER (2007)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer - The Pre-Operative Arimidex Compared to Tamoxilen (PROAC7) trial
L Cataliotti et al.
CANCER (2006)
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists
M Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
W Eiermann et al.
ANNALS OF ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study
JGM Klijn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
